NEW YORK, NY / ACCESSWIRE / June 5, 2017 / Achillion Pharmaceuticals randomly saw its share price head higher on Friday despite any remarkable news. The company received a $6 price target last month however traders are waiting for a phase 2b study with Achillion's odalasvir drug candidate. TG Therapeutics also saw shares climb on Friday after traders were eagerly waiting for phase 3 trial results regarding the company's ublituximab, which were released over the weekend and were positive.

RDI Initiates Coverage on:

Achillion Pharmaceuticals, Inc.
https://ub.rdinvesting.com/news/?ticker=ACHN

TG Therapeutics, Inc.
https://ub.rdinvesting.com/news/?ticker=TGTX

Achillion Pharmaceuticals, Inc. shares closed up 11.53% on Friday despite any significant news. It was back in May however that the company received an impressive price target from firm Leerink. Analyst Joseph Schwartz gave the company an Outperform rating with a $6 price target and said the company offers an attractive risk/reward opportunity, if the company's J&J HCV partnership remains intact. It was back in 2015 that Achillion licensed its hepatitis C drug pipeline to Johnson & Johnson. In April J&J released data from a phase 2 combination drug trial that includes Achillion's odalasvir, which showed that the three-drug approach had 100% cure rates in genotype 1 patients who did not have cirrhosis after six or eight weeks of therapy. Unfortunately, the drug failed to hit its mark in genotype 3 patients. A phase 2b study is set for later this year.

Access RDI's Achillion Pharmaceuticals, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=ACHN

TG Therapeutics, Inc. shares exploded on Friday and closed up 17.37% as the company announced results from its phase 3 GENUINE trial testing of the company's blood cancer candidate ublituximab in combination with Imbruvica which is sold by Johnson & Johnson as well as AbbVie. The results were released at the American Society of Clinical Oncology over the weekend and they were positive. The trial tested both drugs in previously treated high risk Chronic Lymphocytic Leukemia patients. CEO of TG Therapeutics stated, "Patients with high-risk CLL have the poorest outcomes on ibrutinib and are in need of a more efficacious treatment. We believe the data presented today demonstrate that the addition of TG-1101 to ibrutinib improves patient outcomes across multiple measures." He went on to say, "We look forward to sharing these data with the FDA later this year to discuss filing for accelerated approval. We would like to thank our investigators and their patients for their participation in this important clinical trial." It was back in March that top-line data for the trial revealed that high-risk chronic lymphocytic leukemia patients who received ublituximab plus Imbruvica had an 80% overall response rate compared to 47% in patients that only received Imbruvica.

Access RDI's TG Therapeutics Research Report at:
https://ub.rdinvesting.com/news/?ticker=TGTX

Our Actionable Research on Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and TG Therapeutics, Inc. (NASDAQ: TGTX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com